Palonosetron Fresenius Kabi (Palonosetron Hydrochloride)

Palonosetron Hydrochloride, the active ingredient in Palonosetron Fresenius Kabi, is a 5-HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron Fresenius Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting associated with chemotherapy. - Chemotherapy‑induced nausea and vomiting (CINV): Provides long‑lasting prevention of acute and delayed episodes. - Post‑operative nausea and vomiting (PONV): Reduces incidence when administered before surgery. - Radiotherapy‑induced nausea and vomiting: Helps control nausea related to radiation treatment. - Antiemesis in patients receiving highly‑emetic agents: Offers extended protection over older 5‑HT3 antagonists. - Adjunctive anti‑emetic therapy: Used in combination with other anti‑emetics for broader coverage. - Prevention of vom ​ ​   ​  ​  ​  ​  ​  ​  ​  ​